We are live on ! Find out more
PPBT

Purple Biotech
PPBT

17 hedge funds and large institutions have $4.25M invested in Purple Biotech in 2020 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

129% more capital invested

Capital invested by funds: $1.86M → $4.25M (+$2.39M)

13% more funds holding

Funds holding: 15 → 17 (+2)

0% more ownership

Funds ownership: 0% → 0% (+0%)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $2K

Holders
17
Holders Change
+2
Holders Change %
+13.33%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
4
Reduced
1
Closed
2
Calls
–
Puts
$2K
Net Calls
-$2K
Net Calls Change
-$2K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$2.06M
2
Renaissance Technologies
Renaissance Technologies
New York
+$544K
3
VF
Virtu Financial
New York
+$96.9K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$86.8K
5
UBS Group
UBS Group
Switzerland
+$76.7K

Top Sellers

Rank Fund Capital Flow
1
BFC
Bedel Financial Consulting
Indiana
-$11K
2
Osaic Holdings
Osaic Holdings
Arizona
-$2.53K
3
IA
IFP Advisors
Florida
-$843
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
1
Morgan Stanley
New York
$1.89M +$2.06M +2,443 +7,881%
O
2
OrbiMed
New York
$1.32M – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$491K +$544K +645 New
SFI
4
Susquehanna Fundamental Investments
Pennsylvania
$110K – – –
Goldman Sachs
5
Goldman Sachs
New York
$100K +$62.4K +74 +130%
VF
6
Virtu Financial
New York
$88K +$96.9K +115 New
UBS Group
7
UBS Group
Switzerland
$79K +$76.7K +91 +758%
Susquehanna International Group
8
Susquehanna International Group
Pennsylvania
$79K +$86.8K +103 New
WTB
9
Washington Trust Bank
Washington
$63K +$69.1K +82 New
TPWA
10
TRUE Private Wealth Advisors
Oregon
$25K +$18.5K +22 +183%
ASN
11
Advisory Services Network
Georgia
$7K – – –
Osaic Holdings
12
Osaic Holdings
Arizona
$2K -$2.53K -3 -60%
YAL
13
Your Advocates Ltd
Texas
$2K – – –
NSIM
14
North Star Investment Management
Illinois
$1K – – –
RFA
15
Reilly Financial Advisors
California
$1K – – –
BFC
16
Bedel Financial Consulting
Indiana
– -$11K -13 Closed
IA
17
IFP Advisors
Florida
– -$843 -1 Closed
Simplex Trading
18
Simplex Trading
Illinois
– +$843 +1 New

PPBT Hedge Fund Activity: Q4 2020 in Review

17 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Purple Biotech (PPBT) for Q4 2020, worth a combined $4.25M — up 129% from $1.86M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new PPBT positions and 2 closed out — a net gain of 3 holders — while 4 added to existing stakes and 1 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $2.06M. The largest seller was Bedel Financial Consulting, exiting entirely with an estimated $11K sold.

  • 17 institutional investors held Purple Biotech (PPBT) as of Q4 2020, up from 15 in Q3 2020.
  • Funds reported $4.25M of Purple Biotech stock for Q4 2020, up 129% quarter-over-quarter.
  • 5 funds opened new Purple Biotech positions in Q4 2020 and 2 closed out, a net change of +3 holders.
  • The largest Purple Biotech buyer in Q4 2020 was Morgan Stanley, an estimated $2.06M added.
  • The largest Purple Biotech seller in Q4 2020 was Bedel Financial Consulting, an estimated $11K sold.

Based on aggregated 13F filings for Q4 2020.